BioSpace News Archive

Foresee Pharmaceuticals, announced that the company and its collaborators presented a poster at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases, taking place June 19-21, 2023 in Stockholm, Sweden.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced promising interim data, including up to 24 months of follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.

Monopar Therapeutics Inc. today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a panel discussion at the “Radiopharma Forum by the Lake” on Monday June 26, 2023, at 6:15pm CT at the Chicago Club.

Metavention, Inc. has received US Food & Drug Administration approval to initiate its RADAR Pivotal IDE study to determine the safety and efficacy of their Integrated Radio Frequency Renal Denervation System, for the treatment of hypertension.

ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime Capital with Omega Funds.

Ozette Technologies, Inc. today announced its collaboration with Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers.

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review.

Anumana, Inc has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the early identification of cardiac amyloidosis, a life-threatening, rare, underdiagnosed cause of heart failure.

Alentis Therapeutics announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board.

Xeris Biopharma Holdings, Inc. today announced that the first participant has been dosed in a multi-center, open label, Phase 2 study of XP-8121 for the treatment of adults with hypothyroidism.